Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NRIX Nurix Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: NRIX
Price (delayed)
$12.16
Market cap
$927.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.8
Enterprise value
$876.83M
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer
Highlights
NRIX's debt is down by 9% year-on-year and by 6% since the previous quarter
NRIX's equity has surged by 185% year-on-year but it is down by 9% since the previous quarter
NRIX's quick ratio has surged by 119% year-on-year but it is down by 3.9% since the previous quarter
The net income has declined by 44% year-on-year and by 8% since the previous quarter
Key stats
What are the main financial stats of NRIX
Market
Valuations
Earnings
Shares outstanding
76.24M
Market cap
$927.02M
Enterprise value
$876.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.92
Price to sales (P/S)
18.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.54
Revenue
$56.42M
Gross profit
$56.42M
Operating income
-$230.67M
Net income
-$208.4M
EBIT
-$208.22M
EBITDA
-$191.55M
Free cash flow
-$201.59M
Per share
Balance sheet
Liquidity
EPS
-$2.8
EPS diluted
-$2.8
Free cash flow per share
-$2.41
Book value per share
$6.34
Revenue per share
$0.68
TBVPS
$7.36
Total assets
$615.04M
Total liabilities
$134.13M
Debt
$26.62M
Equity
$480.92M
Working capital
$473.72M
Debt to equity
0.06
Current ratio
6.26
Quick ratio
6.12
Net debt/EBITDA
0.26
Margins
Efficiency
Dividend
EBITDA margin
-339.5%
Gross margin
100%
Net margin
-369.4%
Operating margin
-408.9%
Return on assets
-36.1%
Return on equity
-47.5%
Return on invested capital
-50.1%
Return on capital employed
-39.7%
Return on sales
-369.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NRIX stock price
How has the Nurix Therapeutics stock price performed over time
Intraday
0.66%
1 week
21.12%
1 month
7.9%
1 year
-23.76%
YTD
-35.46%
QTD
2.36%
Financial performance
How have Nurix Therapeutics's revenue and profit performed over time
Revenue
$56.42M
Gross profit
$56.42M
Operating income
-$230.67M
Net income
-$208.4M
Gross margin
100%
Net margin
-369.4%
Nurix Therapeutics's operating margin has shrunk by 110% YoY and by 4.7% QoQ
NRIX's net margin has dropped by 106% year-on-year and by 4.1% since the previous quarter
The operating income has declined by 47% year-on-year and by 8% since the previous quarter
The net income has declined by 44% year-on-year and by 8% since the previous quarter
Price vs fundamentals
How does NRIX's price correlate with its fundamentals
Growth
What is Nurix Therapeutics's growth rate over time
Valuation
What is Nurix Therapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
18.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.54
NRIX's EPS is down by 5% year-on-year but it is up by 2.8% since the previous quarter
NRIX's equity has surged by 185% year-on-year but it is down by 9% since the previous quarter
The stock's price to book (P/B) is 36% less than its last 4 quarters average of 3.0 and 34% less than its 5-year quarterly average of 2.9
The revenue has contracted by 30% YoY but it has grown by 3.4% from the previous quarter
The stock's price to sales (P/S) is 30% less than its 5-year quarterly average of 25.7 and 27% less than its last 4 quarters average of 24.6
Efficiency
How efficient is Nurix Therapeutics business performance
NRIX's return on sales has dropped by 106% year-on-year and by 4.1% since the previous quarter
The ROE has grown by 29% YoY and by 11% from the previous quarter
NRIX's return on invested capital is up by 23% year-on-year and by 10% since the previous quarter
NRIX's return on assets is up by 17% year-on-year and by 6% since the previous quarter
Dividends
What is NRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NRIX.
Financial health
How did Nurix Therapeutics financials performed over time
NRIX's current ratio has surged by 119% year-on-year but it is down by 3.1% since the previous quarter
NRIX's quick ratio has surged by 119% year-on-year but it is down by 3.9% since the previous quarter
NRIX's debt is 94% smaller than its equity
NRIX's equity has surged by 185% year-on-year but it is down by 9% since the previous quarter
The debt to equity has dropped by 65% year-on-year but it has increased by 20% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.